Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study

Completed

• Conditions: Breast Cancer

• Registration Number: NCT00185809
• Lead Sponsor: Stanford University

Brief Summary

The purpose of this study is to examine breast cancers that express the protein (NIS) that may be found in malignant breast tissues and to evaluate proteins found in blood and their relationship to NIS, to test whether iodide can be concentrated by breast cells to possibly treat some breast cancers with radioactive iodine, and to calculate the amount of radioactive iodine entering breast cancer cells, how long your cancer retains the agent as well as how much is taken up by other organs, particularly the thyroid gland.

Detailed Description

To demonstrate iodide uptake capacity of breast cancer metastases by imaging women with iodide radioisotope (123I) and calculating potential ablative dose of radioactive iodide (131I).

Study Timeline

• Study Start: 2000-11
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-16
• Primary Completion: 2008-08
• Study Completion: 2008-08
• Status Verified: 2010-07
• Last Update Submitted: 2010-07-16
• Last Update Posted: 2010-07-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 25

Inclusion Criteria

• Only women diagnosed with breast cancer

• 18 years of age or older
• From whom informed consent can be obtained
• Patient is able to provide a fluid (e.g. cyst fluid)
• Patient with blood test that shows protein may allow iodide to accumulate in breast tissue
• Patient who's breast cancer cells accumulated I123 and held on to it for 24 hours

Exclusion Criteria

• Males

• Children

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States